Document Detail


Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
MedLine Citation:
PMID:  20944158     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Wilms' tumour gene 1 (WT1), a highly ranked immunotherapeutic target, is expressed in uterine cancer and therefore WT1 immunotherapy may present an attractive treatment option. PATIENT AND METHODS: An HLA-A2.1-positive 46-year-old woman with end-stage serous endometrial cancer received 4 weekly injections of WT1-RNA-loaded dendritic cells. Response was measured clinically (CT scan), biochemically (CA125) and immunologically (WT1-specific T cells). RESULTS: The patient showed WT1 positivity in 10% of tumour cells and diffusely in the intratumoural endothelial cells of the recurrent disease. After 2 injections, CA125 started to decrease and WT1-specific T-cells increased 2.5-fold. The treatment was feasible and there were no treatment-related side-effects. However, the patient, suffering from diffuse disease which became progressive again, died 8 months later. CONCLUSION: This is the first patient with a WT1-positive endometrial carcinoma, to receive immunotherapy with WT1-RNA-loaded dendritic cells, resulting in a vaccine-specific T cell response.
Authors:
Ann Coosemans; Matthias Wölfl; Zwi N Berneman; Viggo Van Tendeloo; Ignace Vergote; Frédéric Amant; Stefaan W Van Gool
Related Documents :
2448218 - Sarcomatous wilms' tumour with clear cells and hyalinization. a study of 38 tumours in ...
11677118 - E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.
934698 - Fine structure and origin of kaposi's sarcoma.
14731718 - The retinoblastoma protein as a transcriptional repressor.
24165938 - Extracellular cell wall β(1,3)glucan is required to couple septation to actomyosin rin...
19301208 - The antifibrogenic effect of hepatocyte growth factor (hgf) on renal tubular (hk-2) cel...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  30     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-10-14     Completed Date:  2010-11-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  3709-14     Citation Subset:  IM    
Affiliation:
Department of Child and Women, UZ Gasthuisberg, Katholieke Universiteit Leuven, Belgium. an.coosemans@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cancer Vaccines / immunology,  therapeutic use*
Dendritic Cells / immunology*
Endometrial Neoplasms / immunology,  pathology,  therapy*
Female
Humans
Immunotherapy / methods*
Middle Aged
Neoplasm Recurrence, Local / therapy
Neoplasm Staging
RNA, Messenger / immunology
T-Lymphocytes, Cytotoxic / immunology
WT1 Proteins / immunology*
Chemical
Reg. No./Substance:
0/Cancer Vaccines; 0/RNA, Messenger; 0/WT1 Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gastric tumor from metastasis of breast cancer.
Next Document:  Targeted Therapy for Ewing's Sarcoma: Significance of Heterogeneity.